PPOS 和 GnRH 拮抗剂方案在接受 PGT-A 的 PCOS 女性中囊胚整倍体率的比较
一项比较 PPOS(孕激素促卵巢刺激)方案和促性腺激素释放激素 (GnRH) 拮抗剂方案在接受 PGT-A(植入前基因检测)的 PCOS(多囊卵巢综合征)女性中囊胚整倍体率的随机对照试验对于非整倍体)
This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups:
Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger.
The primary outcome is the euploidy rate of blastocysts.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:HE LI, MD
- 电话号码:+8613817223099
- 邮箱:lihe198900@163.com
研究联系人备份
- 姓名:XIAOXI SUN, PHD
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Women age between 20 and 37 years.
- Women diagnosed with PCOS according to the modified Rotterdam criteria: oligomenorrhea or amenorrhea, together with the presence of ≥12 antral follicles (≤9 mm) and/or ovarian volume >10 mL on transvaginal ultrasonographic scanning, and/or clinical/ biochemical hyperandrogenism. Other causes of hyperandrogenism and ovulation dysfunction-including tumours, congenital adrenal hyperplasia, hyperprolactinaemia and thyroid dysfunction-were excluded
Exclusion Criteria:
- Presence of a functional ovarian cyst with E2>100 pg/mL
- Endometriosis grade 3 or higher
- Repeated implantation failure (>=4 embryos replaced or >=2 blastocysts replaced without success)
- Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)
- Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease;
- Recipient of oocyte donation
- Presence of hydrosalpinx which is not surgically treated
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Antagonist group
Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. |
GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
其他名称:
|
|
实验性的:PPOS group
Women will receive oral MPA 10mg qd from Day 3 till the day of ovulation trigger. |
oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
euploidy rate
大体时间:1 month after oocyte retrieval
|
euploidy rate of blastocysts |
1 month after oocyte retrieval
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
live birth rate
大体时间:1 year after embryo transfer
|
deliveries ≥22 weeks gestation with heartbeat and breath of the first frozen embryo transfer |
1 year after embryo transfer
|
|
cumulative live birth rate
大体时间:1 year after embryo transfer
|
cumulative live birth within 6 months of randomization |
1 year after embryo transfer
|
|
ongoing pregnancy
大体时间:12 weeks' gestation
|
a viable pregnancy beyond 12 weeks' gestation of the first frozen embryo transfer |
12 weeks' gestation
|
|
number of oocytes retrieved
大体时间:1 day after oocyte retrieval
|
number of oocytes retrieved |
1 day after oocyte retrieval
|
|
OHSS(ovarian hyperstimulation syndrome)
大体时间:1 month after ovarian stimulation
|
Moderate or severe ovarian hyperstimulation syndrome.Ovarian hyperstimulation syndrome (OHSS) is diagnosed and classified according to the Royal College of Obstetricians and Gynaecologists guideline. Green-top guideline No.5. Ovarian hyperstimulation syndrome. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg5/ (accessed 26 Feb 2016). |
1 month after ovarian stimulation
|
|
birthweight of newborns
大体时间:1 year after embryo transfer
|
birthweight of newborns |
1 year after embryo transfer
|
合作者和调查者
调查人员
- 首席研究员:XIAOXI SUN, PHD、Shanghai JiAi Genetics & IVF Institute, China
出版物和有用的链接
一般刊物
- Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015 Jul;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022. Epub 2015 May 5.
- Begueria R, Garcia D, Vassena R, Rodriguez A. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod. 2019 May 1;34(5):872-880. doi: 10.1093/humrep/dez034.
- Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017 Mar 1;23(2):211-220. doi: 10.1093/humupd/dmw047.
- Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan;91(1):48-53. doi: 10.1210/jc.2005-1329. Epub 2005 Oct 25.
- Lee E, Illingworth P, Wilton L, Chambers GM. The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review. Hum Reprod. 2015 Feb;30(2):473-83. doi: 10.1093/humrep/deu303. Epub 2014 Nov 28.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- JIAI 2022-03
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Individual participant data that underlie the results after deidentification (text, tables, figures, and appendices) and study protocol will be shared.
IPD 共享时间框架
Data will be available when beginning 3 months and ending 5 years following article publication.
IPD 共享访问标准
To achieve aims in the approved proposal, researchers who provide a methodologically sound proposal will be shared with. Proposals should be sent to lihe198900@163.com.
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.